Prasco Laboratories Oct. 17 announced it has signed an exclusive distribution and supply agreement with Shire for an authorized generic version of Fosrenol (lanthanum carbonate) chewable tablets.
Shire’s Fosrenol is indicated to reduce serum phosphate in patients with end-stage renal disease.
As part of the agreement, Prasco will market the authorized generic version of the drug in the U.S. in 500 mg, 750 mg and 1000 mg strengths.
Authorized generics are prescription drugs produced by brand pharmaceutical companies and marketed under a private label, at generic prices.
Prasco is based in Mason, Ohio, and Shire is based in Dublin.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.